AMRI, a contract research, development, and manufacturing organization, has launched a new multipurpose aseptic active pharmaceutical ingredient (API) line at the company’s facility in Valladolid, Spain.

The line, which was officially opened May 9, 2018, was announced in November 2017 and enhances capacity at the site while adding to AMRI’s other aseptic API manufacturing plants in Bon Encontre and Tonneins, France.

AMRI says its lines are designed to meet requirements from pilot-scale to multi-ton scale manufacturing, and can be integrated with API production or operate as a separate outsourced step for customers who do not have bulk sterile facilities or who may need additional capacity. Further integration is offered with AMRI’s drug-product capabilities.

The investment, coupled with AMRI’s build-out of analytical services and a new warehouse, provides additional capacity and technology for sterile APIs.

Source: AMRI